Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Harold Storey
Perrigo Co. v. AbbVie Inc. - Third Circuit Holds Mutual Release Bars Generic Drug Company's Antitrust Claim | JD Supra
January 11, 2023 To embed, copy and paste the code into your website or blog: On 21 July 2022, the Third Circuit in Perrigo Co. v. AbbVie Inc. affirmed the district court’s judgment that the mutual release in the settlement agreement between the parties from an earlier patent infringement and Hatch-Waxman Act litigation barred plaintiffs’ subsequent antirust claim.1 BACKGROUND In 2000, Defendants AbbVie Inc.
Perrigo Co. v. Abbvie Inc. - Third Circuit Holds Mutual Release Bars Generic Drug Company’s Antitrust Claim Alleging That “Sham” Patent Infringement Litigation Delayed Generic Drug Launch
On 21 July 2022, the Third Circuit in Perrigo Co. v. AbbVie Inc. affirmed the district court’s judgment that the mutual release in the settlement agreement between the parties from an earlier patent infringement and Hatch-Waxman Act litigation barred plaintiffs’ subsequent antirust claim.1 BACKGROUND In 2000, Defendants AbbVie Inc.
New FDA Draft Guidance Aiming To Prevent Drug Shortages Will Affect Pharmaceutical Manufacturers | JD Supra
The U.S. Food and Drug Administration (FDA) has taken formal steps to prevent and mitigate drug shortages for over a decade. While the problem predates the COVID-19 pandemic, the pandemic presented potential new challenges for drug manufacturing, supply, and distribution.1 To address those challenges, Congress enacted the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) in March 2020.
New FDA Draft Guidance Aiming to Prevent Drug Shortages Will Affect Pharmaceutical Manufacturers
The U.S. Food and Drug Administration (FDA) has taken formal steps to prevent and mitigate drug shortages for over a decade. While the problem predates the COVID-19 pandemic, the pandemic presented potential new challenges for drug manufacturing, supply, and distribution.1 To address those challenges, Congress enacted the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) in March 2020.
My Inheritance - By Lynelle Mason
If someone told you that you had inherited a million dollars, what would you say? What would you do? My guess is you’d be leaping in the air with wild thoughts running through your mind of living on Easy Street for the rest of your life. The things Mason has inherited, both the good and the not-so-good, have little to do with money. Among her inheritances are the genes given to her by her parents and ancestors. The places where Mason has lived have left their marks on her, some happy and some sad.
Remicade® Update: Passing Up Your Chance to Dance Can Increase Damages
On March 2, 2017, U.S. District Court Judge Mark Wolf provided guidance for determining the appropriate measure of damages in Janssen Biotech, Inc. v. Celltrion Healthcare Co.[1] In particular, Judge Wolf described the framework he would apply if plaintiff Janssen Biotech, Inc. (“Janssen”) is able to prove that defendants Celltrion Healthcare, Co. and Celltrion, Inc. and Hospira, Inc. (together, “Celltrion”) infringed U.S. Patent No. 7,598,083 (the “’083 patent”).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Harold
Contact Harold, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack